<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Biol. Psychiatry</journal-id><journal-title-group><journal-title>Biological Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0006-3223</issn><issn pub-type="epub">1873-2402</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22364739</article-id><article-id pub-id-type="pmc">3314969</article-id><article-id pub-id-type="publisher-id">S0006-3223(11)01273-X</article-id><article-id pub-id-type="doi">10.1016/j.biopsych.2011.12.023</article-id><article-categories><subj-group subj-group-type="heading"><subject>Archival Report</subject></subj-group></article-categories><title-group><article-title><italic>COMT</italic> Val<sup>158</sup>Met Genotype Determines the Direction of Cognitive Effects Produced by Catechol-<italic>O</italic>-Methyltransferase Inhibition</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farrell</surname><given-names>Sarah M.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Tunbridge</surname><given-names>Elizabeth M.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Braeutigam</surname><given-names>Sven</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Harrison</surname><given-names>Paul J.</given-names></name><email>paul.harrison@psych.ox.ac.uk</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom</aff><aff id="aff2"><label>b</label>Oxford Centre for Human Brain Activity, University of Oxford, Warneford Hospital, Oxford, United Kingdom</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Address correspondence to: Paul J. Harrison, DM, FRCPsych, Neurosciences Building, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK <email>paul.harrison@psych.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>15</day><month>3</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><day>15</day><month>3</month><year>2012</year></pub-date><volume>71</volume><issue>6</issue><fpage>538</fpage><lpage>544</lpage><history><date date-type="received"><day>31</day><month>10</month><year>2011</year></date><date date-type="rev-recd"><day>23</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; 2012 Elsevier Inc.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Society of Biological Psychiatry</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>Open Access under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</ext-link> license</license-p></license></permissions><abstract><sec><title>Background</title><p>Catechol-<italic>O</italic>-methyltransferase (COMT) metabolizes dopamine. The <italic>COMT</italic> Val<sup>158</sup>Met polymorphism influences its activity, and multiple neural correlates of this genotype on dopaminergic phenotypes, especially working memory, have been reported. COMT activity can also be regulated pharmacologically by COMT inhibitors. The inverted-U relationship between cortical dopamine signaling and working memory predicts that the effects of COMT inhibition will differ according to <italic>COMT</italic> genotype.</p></sec><sec><title>Methods</title><p>Thirty-four <italic>COMT</italic> Met<sup>158</sup>Met (Met-COMT) and 33 <italic>COMT</italic> Val<sup>158</sup>Val (Val-COMT) men were given a single 200-mg dose of the brain-penetrant COMT inhibitor tolcapone or placebo in a randomized, double-blind, between-subjects design. They completed the N-back task of working memory and a gambling task.</p></sec><sec><title>Results</title><p>In the placebo group, Met-COMT subjects outperformed Val-COMT subjects on the 2- back, and they were more risk averse. Tolcapone had opposite effects in the two genotype groups: it worsened N-back performance in Met-COMT subjects but enhanced it in Val-COMT subjects. Tolcapone made Met-COMT subjects less risk averse but Val-COMT subjects more so. In both tasks, tolcapone reversed the baseline genotype differences.</p></sec><sec><title>Conclusions</title><p>Depending on genotype, COMT inhibition can enhance or impair working memory and increase or decrease risky decision making. To our knowledge, the data are the clearest demonstration to date that the direction of effect of a drug can be influenced by a polymorphism in its target gene. The results support the inverted-U model of dopamine function. The findings are of translational relevance, because COMT inhibitors are used in the adjunctive treatment of Parkinson's disease and are under evaluation in schizophrenia and other disorders.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Catechol-<italic>o</italic>-methyltransferase</kwd><kwd>decision making</kwd><kwd>pharmacogenetics</kwd><kwd>polymorphism</kwd><kwd>tolcapone</kwd><kwd>working memory</kwd></kwd-group></article-meta></front><body><p>An inverted-U relationship has been proposed between dopamine and prefrontal cortex function in which too little or too much dopamine signaling impairs working memory (<xref rid="bib1 bib2 bib3 bib4" ref-type="bibr">1&#x02013;4</xref>). Both genetic and pharmacologic factors can affect position on the curve. The enzyme catechol-<italic>O</italic>-methyltransferase (COMT) metabolizes dopamine and is one such influence (<xref rid="bib5 bib6 bib7 bib8 bib9" ref-type="bibr">5&#x02013;9</xref>). COMT activity is genetically influenced, with the greatest variance explained by a common polymorphism, Val<sup>158</sup>Met, which is associated with a approximately 35% enzyme activity difference between homozygotes (Val-COMT &#x0003e; Met-COMT) in human brain (<xref rid="bib10" ref-type="bibr">10</xref>); this is reflected in a genotype difference in cortical D1 dopamine receptor availability, a proxy measure of cortical dopamine (<xref rid="bib11" ref-type="bibr">11</xref>). In turn, as shown initially by Egan <italic>et al.</italic> (<xref rid="bib12" ref-type="bibr">12</xref>) and confirmed in many other studies (<xref rid="bib13" ref-type="bibr">13</xref>), there are robust Val<sup>158</sup>Met genotype effects on cortical activation during tasks of working memory and executive function. Val<sup>158</sup>Met genotype differences in working memory performance have also been reported (<xref rid="bib12 bib14" ref-type="bibr">12,14</xref>), although less consistently (<xref rid="bib15" ref-type="bibr">15</xref>). COMT activity can also be regulated pharmacologically by COMT inhibitors, with corresponding cognitive, behavioral, and neurochemical effects, in rodents (<xref rid="bib16 bib17" ref-type="bibr">16,17</xref>) and humans (<xref rid="bib18 bib19 bib20 bib21" ref-type="bibr">18&#x02013;21</xref>).</p><p>The inverted-U model predicts that COMT inhibition should have differential effects on working memory depending on Val<sup>158</sup>Met genotype. That is, the effect of being moved rightward on the curve (because COMT inhibition increases prefrontal dopamine) (<xref rid="bib16" ref-type="bibr">16</xref>) will be affected by the starting position: Val-COMT subjects, with their higher COMT activity, sit to the left of Met-COMT subjects. COMT inhibition will thus tend to move Val-COMT subjects closer to the optimum and enhance performance, whilst moving Met-COMT subjects beyond the peak and impairing performance. To date, tests of this focused pharmacogenetic hypothesis are intriguing but inconclusive (<xref rid="bib19 bib20" ref-type="bibr">19,20</xref>), although <italic>COMT</italic> Val<sup>158</sup>Met genotype has been shown to modulate responses to other dopaminergic drugs including amphetamine (<xref rid="bib22" ref-type="bibr">22</xref>), antipsychotics (<xref rid="bib23" ref-type="bibr">23</xref>), and methylphenidate (<xref rid="bib24" ref-type="bibr">24</xref>).</p><p>Here we recruited Val-COMT and Met-COMT homozygote men, gave them the brain-penetrant COMT inhibitor tolcapone (<xref rid="bib25 bib26" ref-type="bibr">25,26</xref>), or placebo, and measured their performance on the N-back task of working memory. Because the possibility that an inverted-U relationship may extend to other dopamine-modulated phenotypes remains less well explored, we also tested the subjects' performance on a gambling task.</p><sec sec-type="materials|methods" id="sec1"><title>Methods and Materials</title><sec id="sec1.1"><title>Participants</title><p>The study was approved by the Oxfordshire National Health Service Research Ethics Committee B (09/H0605/69). Healthy men aged 18 to 50 years old were recruited by advertisement. They had no history of psychiatric or neurologic disorder, and none were taking psychotropic medication. Alcohol and smoking use was recorded, and all subjects denied use of illicit substances. Subjects with alcohol intake greater than 30 units/week or a history of liver disease were excluded because of the hepatotoxicity risk with tolcapone. Participants were genotyped for the Val<sup>158</sup>Met polymorphism. We selected only homozygotes (Met-COMT and Val-COMT), because these represent low and high COMT activity, respectively, with heterozygotes being intermediate (<xref rid="bib10" ref-type="bibr">10</xref>) and therefore less informative in the present context. The subjects were unrelated to each other. Sixty-seven subjects performed the gambling task, 60 of whom also carried out the N-back (<xref rid="tbl1" ref-type="table">Table 1</xref>). Subjects completed the National Adult Reading Test and depression and anxiety inventories. On the day of testing, they completed visual analogue scale (VAS) ratings of alertness, drowsiness, happiness, sadness, anxiety, and nausea; these were completed on arrival and again approximately 90 min and then approximately 120 min later.</p><p>Within each genotype group, subjects were randomly assigned to tolcapone (200 mg by mouth) or placebo. A between-subjects design was chosen to avoid order or practice effects. The study was double-blind, with matching capsules prepared by a pharmacy registered under U.K. Good Manufacturing Practice regulations. Tolcapone has an elimination half-life of 2.0 &#x000b1; .8 hours, and the dose given produces 70% to 80% peripheral blood COMT inhibition between 1 and 4 hours (<xref rid="bib25 bib27" ref-type="bibr">25,27</xref>). Testing began 90 min after swallowing the capsule and lasted &#x0223c;90 min. Testing was carried out while subjects were in a magnetoencephalography (MEG) scanner; MEG results will be reported separately. After testing, subjects were asked to guess whether they had received tolcapone or placebo.</p></sec><sec id="sec1.2"><title>Genotyping</title><p>DNA was extracted from buccal swabs and genotyped for Val<sup>158</sup>Met using the appropriate Taqman SNP Genotyping Assay (Applied Biosystems, Carlsbad, California), in duplicate. A subset of genotypes were confirmed using a restriction fragment length polymorphism assay (<xref rid="bib28" ref-type="bibr">28</xref>). Genotype calls agreed in all cases. No other polymorphisms were measured, reflecting the hypothesis-driven nature of the study.</p></sec><sec id="sec1.3"><title>N-Back Task of Working Memory</title><p>In the N-back task as instantiated here, a number between 1 and 4 is shown at random on a screen. For the 0-back, subjects respond to the number currently showing on the screen by pressing the appropriate button; for the 1-back, subjects respond to the previous number on the screen, and so on for 2- and 3-back conditions. Each number is shown for 160 msec, with an interval of 1640 msec between numbers (and 3000 msec between blocks). The task imposes a parametric load on working memory, and the version we used is relatively demanding (<xref rid="bib29" ref-type="bibr">29</xref>). The primary performance measure is accuracy (correct responses); we also measured reaction time (RT).</p></sec><sec id="sec1.4"><title>Gambling Task</title><p>The task involves monetary decision making based on a choice between gambling a high or a low amount (<xref rid="bib30" ref-type="bibr">30</xref>). The task has been used extensively for studies of decision making and risky choice; electroencephalographic responses during the task are sensitive to <italic>COMT</italic> Val<sup>158</sup>Met (<xref rid="bib31" ref-type="bibr">31</xref>). Subjects are given &#x000a3;10 (approximately $15) to play with. Two gray boxes are shown on a screen, with &#x0201c;5&#x0201d; or &#x0201c;25&#x0201d; shown within each box. The subject selects one box, and the choice means they are gambling either 5 or 25 pence. Once the choice is made, the boxes change color, either to green (indicating a win) or to red (indicating a loss). Both boxes may go red, both green, or one of each. Thus, a subject can win when they could have lost, lose when they could have won, win a small amount when they could have won a large amount, and so on. Intermittently, the screen shows how much money is currently banked. The primary measure of interest is simply the percentage of bets that were &#x0201c;5&#x0201d; not &#x0201c;25.&#x0201d; We also calculated this for bets that followed two successive wins, or two successive losses, because Val<sup>158</sup>Met genotype has been reported to affect sensitivity to losses versus rewards (<xref rid="bib32 bib33" ref-type="bibr">32,33</xref>).</p></sec><sec id="sec1.5"><title>Statistical Analysis</title><p>Analyses were carried out in SPSS for Windows (version 17.0; SPSS Statistics Inc., Chicago, Illinois). For the N-back, we first conducted a repeated-measures analysis of variance (ANOVA), with difficulty (back condition) as the within-subjects factor and drug and genotype as the between-subjects factors. Each back condition was then examined with a two-way ANOVA with drug and genotype as between-subjects factors. Post hoc comparisons were made using <italic>t</italic> tests (two-tailed). For the gambling task, we used two-way ANOVA with drug and genotype as between-subjects factors. Correlations between variables were explored using Pearson's coefficient. Significance was set at &#x003b1; = .05.</p></sec></sec><sec sec-type="results" id="sec2"><title>Results</title><p>The drug blind was maintained, with 59 of the 67 subjects thinking that they had received placebo, including 30 of the 33 who had in fact had tolcapone.</p><sec id="sec2.1"><title>N-Back Performance</title><p>There were no main effects of drug or genotype on N-back accuracy, nor interactions between drug or genotype and difficulty. There was a genotype &#x000d7; drug &#x000d7; difficulty interaction from 0-back to 3-back [<italic>F</italic>(2.33,130.3) = 3.9, <italic>p</italic> = .018], and a genotype &#x000d7; drug interaction for all conditions (<xref rid="fig1" ref-type="fig">Figure 1</xref> and <xref rid="sec6" ref-type="sec">Figure S1A in Supplement 1</xref>).</p><p>The most striking results were seen for the 2-back (<xref rid="fig1" ref-type="fig">Figure 1</xref>C). On placebo, Met-COMT subjects out-performed Val-COMT subjects (<italic>p =</italic> .006), but in the tolcapone group, this difference was reversed such that Val-COMT subjects outperformed Met-COMT subjects (<italic>p =</italic> .022); tolcapone significantly impaired performance in Met-COMT subjects (<italic>p =</italic> .019) and improved it in Val-COMT subjects (<italic>p =</italic> .007). For the 0- and 1-back, on placebo, Met-COMT and Val-COMT subjects performed similarly, but accuracy was impaired in Met-COMT subjects given tolcapone compared with those given placebo (0-back, <italic>p =</italic> .002; 1-back, <italic>p =</italic> .043; <xref rid="fig1" ref-type="fig">Figure 1</xref>A and <xref rid="fig1" ref-type="fig">1</xref>B). Consequently, in subjects given tolcapone, Val-COMT subjects performed better than Met-COMT subjects (0-back, <italic>p =</italic> .017; 1-back, <italic>p =</italic> .013). Results for the 3-back were similar to the 2-back but less significant (<xref rid="fig1" ref-type="fig">Figure 1</xref>D). The genotype &#x000d7; drug interaction accounted for 19% of overall N-back performance (partial h<sup>2</sup>), and for 13.5%, 9%, 15.5%, and 9% of the variance in 0, 1, 2, and 3-back performance, respectively (adjusted <italic>R</italic><sup>2</sup>).</p><p>Because a significant drug &#x000d7; genotype interaction was seen for the 0-back condition, in which working memory is not explicitly required, we performed a supplementary analysis to investigate whether COMT affects working memory when 0-back performance is controlled for. For each subject, 1-, 2-, and 3-back performance was expressed as a percentage of 0-back performance and entered into a repeated-measures ANOVA with three levels of difficulty (1-, 2-, and 3-back). This analysis showed a drug &#x000d7; genotype interaction [<italic>F</italic>(1,60) = 9.2; <italic>p =</italic> .004], with Met-COMT subjects outperforming Val-COMT subjects in the placebo groups (<italic>p =</italic> .024) and Val-COMT subjects tending to outperform Met-COMT subjects in the tolcapone groups (<italic>p =</italic> .053). Thus, an interaction between drug and genotype on working memory remained when 0-back performance was taken into account.</p><p>Reaction times for each N-back condition are shown in <xref rid="tbl2" ref-type="table">Table 2</xref> and <xref rid="sec6" ref-type="sec">Figure S1B in the Supplement</xref>. We found a trend-level RT &#x000d7; genotype interaction [<italic>F</italic>(1.86,98.7) = 2.79, <italic>p =</italic> .070], with Met-COMT subjects reacting faster than Val-COMT subjects (<italic>p =</italic> .049). Tolcapone decreased RT in Val-COMT (<italic>p =</italic> .046) but not in Met-COMT (<italic>p =</italic> .61) subjects. On placebo, Met-COMT subjects reacted faster than Val-COMT subjects on the 2-back (<italic>p =</italic> .046) and 3-back (<italic>p =</italic> .039); no genotype differences in RT were seen for subjects on tolcapone.</p></sec><sec id="sec2.2"><title>Gambling Task</title><p>There was a genotype &#x000d7; drug interaction for the size of bet placed [<italic>F</italic>(1,61) = 7.91, <italic>p =</italic> .007]. In the subjects given placebo, Met-COMT subjects made more small bets than Val-COMT subjects (<italic>p =</italic> .05); this difference was reversed in subjects given tolcapone (<italic>p =</italic> .025; <xref rid="fig1" ref-type="fig">Figure 1</xref>E), with tolcapone-treated Val-COMT subjects being more risk averse than tolcapone-treated Met-COMT subjects (<italic>p =</italic> .008). Drug and genotype together explained 8.5% of the variance. As noted, Val<sup>158</sup>Met genotype may affect sensitivity to losses versus rewards (<xref rid="bib32 bib33" ref-type="bibr">32,33</xref>), but our findings were unaffected by the outcomes of prior trials. That is, the main effects and interactions shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>E were also seen for trials following two wins or two losses or other combinations of prior outcomes (<xref rid="tbl2" ref-type="table">Table 2</xref> and data not shown). We found no main effects of drug or genotype, nor interactions, on gambling task RT (<xref rid="tbl2" ref-type="table">Table 2</xref>; all <italic>F</italic>s &#x0003c;1.5, <italic>p</italic> &#x0003e; .3).</p></sec><sec id="sec2.3"><title>Other Measures and Correlations</title><p>On the VAS ratings, Met-COMT subjects rated themselves happier than Val-COMT subjects overall [7.2 &#x000b1; .3 vs. 6.3 &#x000b1; .3; <italic>F</italic>(<xref rid="bib1 bib61" ref-type="bibr">1,61</xref>) = 5.58, <italic>p =</italic> .021], including at baseline [7.1 &#x000b1; .3 vs. 6.0 &#x000b1; .3; <italic>p =</italic> .013]. Happiness also showed a drug &#x000d7; genotype &#x000d7; time interaction [<italic>F</italic>(1.70,103.9) = 3.3, <italic>p =</italic> .037] due to an increase in ratings with time in the Val-COMT tolcapone group (<italic>p =</italic> .015, comparing time points 1 and 3) that was absent in other groups (<xref rid="fig1" ref-type="fig">Figure 1</xref>F). None of the other VAS ratings were affected by genotype or drug (<xref rid="sec6" ref-type="sec">Table S1 in Supplement 1</xref>), nor did the groups differ in their depression and anxiety inventory ratings (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>Because we found drug &#x000d7; genotype interactions on N-back performance, risky decision making, and the happiness VAS rating, we investigated whether these variables correlated with each other. However, there were no significant correlations (&#x02212;.13 &#x0003c; R &#x0003c; .23; all <italic>p</italic>s &#x0003e; .05; <xref rid="sec6" ref-type="sec">Table S2 in Supplement 1</xref>). Neither did inclusion of happiness VAS score as a covariate affect the N-back or gambling task results (data not shown).</p></sec></sec><sec sec-type="discussion" id="sec3"><title>Discussion</title><p>Our study has two main findings. First, on placebo, Met-COMT subjects outperformed Val-COMT on the 2-back task of working memory and were more risk averse. Second, and more notably, genotype interacted with COMT inhibition by tolcapone to affect both these indices. Compared with those given placebo, tolcapone improved working memory in Val-COMT subjects but impaired it in Met-COMT subjects; it made Met-COMT subjects less risk averse and Val-COMT subjects more so. These interactions were qualitative and robust, and the drug effect was sufficient to reverse baseline genotype differences. The effects were also of notable size, with Val<sup>158</sup>Met genotype and tolcapone together accounting for 19% of the variance in N-back performance. This is substantial, especially given that we did not include the contribution of other genetic (<xref rid="bib21 bib34 bib35" ref-type="bibr">21,34,35</xref>) and epigenetic (<xref rid="bib36" ref-type="bibr">36</xref>) sources of COMT variation nor polymorphisms in interacting dopaminergic genes (<xref rid="bib37 bib38 bib39" ref-type="bibr">37&#x02013;39</xref>). These results are significant with regard to the range of phenotypes with which COMT is associated, the inverted-U model of cortical dopamine, and from a pharmacogenetic perspective. Our findings support the hypothesis that <italic>COMT</italic> genotype influences not just the magnitude but the direction of cognitive and behavioral responses to COMT inhibition.</p><p>Our findings that, on placebo, Met-COMT subjects performed better than Val-COMT subjects at the 2-back replicates the result of one large study (<xref rid="bib15 bib40" ref-type="bibr">15,40</xref>) but many other studies (e.g., Blanchard <italic>et al.</italic>) (<xref rid="bib41" ref-type="bibr">41</xref>) and a meta-analysis (<xref rid="bib14" ref-type="bibr">14</xref>) have been negative. The differences likely reflect the fact that the nature of the N-back task differs between different versions; we used one with high updating and interference management demands thought to be more dependent on COMT (<xref rid="bib29 bib42" ref-type="bibr">29,42</xref>). Our task was also relatively difficult, as shown by the performance data, perhaps because subjects were new to the task and given only brief instruction, and they completed it in the MEG scanner. Limiting our study to young men with an above-average and restricted range of verbal IQ (National Adult Reading Test scores ranged from 108 to 125) may also have contributed, given gender- (<xref rid="bib43 bib44" ref-type="bibr">43,44</xref>), age- (<xref rid="bib45 bib46" ref-type="bibr">45,46</xref>), and possibly IQ-related (<xref rid="bib14" ref-type="bibr">14</xref>) variation in COMT function.</p><p>Two prior studies have investigated interactive effects of tolcapone and Val<sup>158</sup>Met on working memory and executive functioning and gave more equivocal results than we report here. Apud and colleagues (<xref rid="bib19" ref-type="bibr">19</xref>) used repeated tolcapone administration (200 mg three times a day for a week) in a within-subjects crossover design. They did not identify any main effects or interactions on N-back accuracy but did find an interaction on intradimensional set shifting, such that tolcapone improved Val-COMT subjects but impaired Met-COMT subjects. Giakoumaki <italic>et al.</italic> (<xref rid="bib20" ref-type="bibr">20</xref>) used a single dose of tolcapone (200 mg) in a within-subjects crossover design. They found no drug &#x000d7; genotype interaction for N-back accuracy but did for N-back RT, which was improved by tolcapone in Val- but not Met-COMT subjects. They also found a trend-level effect on letter-number sequencing, another test of working memory, with tolcapone again selectively improving Val-COMT subjects. Overall, therefore, all studies agree that tolcapone and genotype have interactive effects on executive functioning, with tolcapone enhancing Val-COMT subjects but either not improving or impairing Met-COMT subjects. The demographic and methodological factors mentioned earlier are probably relevant in explaining why we identified more robust drug &#x000d7; genotype interactions, specifically on N-back performance, than did the prior studies; moreover, our sample of homozygotes (<italic>n</italic> = 60&#x02013;67) is considerably larger than the number included in the earlier studies (<italic>n</italic> = 22&#x02013;23).</p><p>Our other findings highlight that COMT has roles in a range of phenotypes beyond executive function and working memory (<xref rid="bib6 bib7" ref-type="bibr">6,7</xref>). First, involvement of COMT in dopaminergic contributions to decision making and reward has hitherto been demonstrated in relatively complex paradigms (<xref rid="bib47 bib48 bib49 bib50" ref-type="bibr">47&#x02013;50</xref>), but our gambling task data show that even the simple trait of risky decision making is affected by COMT: high COMT activity is associated with making a higher proportion of large gambles (risky choices) compared with low COMT activity. This finding may relate to the recent demonstration in rodents that enhanced dopamine signaling via D2 receptors promotes risk aversion (<xref rid="bib51" ref-type="bibr">51</xref>). Second, the effect of tolcapone on 0-back performance suggests an influence of COMT on attention, consistent with prior evidence for COMT modulation of attentional processes (<xref rid="bib52 bib53" ref-type="bibr">52,53</xref>). Third, we found some evidence for an effect on mood state (the happiness VAS), which may relate to evidence linking <italic>COMT</italic> Val<sup>158</sup>Met with affective processing (<xref rid="bib12 bib54" ref-type="bibr">12,54</xref>). However, none of our other trait or state ratings nor the earlier tolcapone studies (<xref rid="bib19 bib20" ref-type="bibr">19,20</xref>) found any effects of tolcapone on affect or well-being, and so we view this result with caution. Nevertheless, the results in total emphasize the pleiotropic nature of COMT and the need to consider affective and attentional contributions to its modulation of working memory or other higher level cognitive processes.</p><p>The genotype &#x000d7; drug interactions support the inverted-U model of dopamine function, and for a genetic and pharmacologic contribution from COMT to this relationship, based on the rationale outlined earlier and illustrated in <xref rid="fig2" ref-type="fig">Figure 2</xref>. The gambling task data highlight that an inverted-U may well apply not only to working memory but to other dopamine-modulated behaviors (<xref rid="bib2 bib4" ref-type="bibr">2,4</xref>). It is possible that the various findings could be explained in terms of different manifestations of a single inverted-U, but the absence of any correlations between COMT's effects on working memory and risky decision making suggests that there is at least a partial separation of the underlying neural circuits and mechanisms. However, in humans, it is difficult to test critically the inverted-U concept or to distinguish between variants of it. Instead, formal testing can better be conducted in pharmacologic studies of humanized transgenic mice that mimic the human Val<sup>158</sup>Met polymorphism (<xref rid="bib55" ref-type="bibr">55</xref>). Such studies will also provide the opportunity to investigate the cellular and synaptic processes involved. For example, the balance between D1 and D2 receptor signaling, high and low D2 receptor affinity states, and other putative mechanisms (<xref rid="bib8" ref-type="bibr">8</xref>).</p><p>In summary, our results provide a striking and &#x0201c;lawful&#x0201d; example of a genotype &#x000d7; drug interaction. That is, the functionality of the gene is known (viz., it metabolizes dopamine), as is that of the Val<sup>158</sup>Met polymorphism (viz., it influences enzyme activity); the drug effectively and selectively targets the protein encoded by the gene; and the predicted effects are grounded in a well-established systems-level model (viz., the inverted-U of cortical dopamine signaling). Such a pharmacogenetically favorable set of circumstances is rare and may explain why, to our knowledge, COMT provides the clearest demonstration to date of a qualitative pharmacogenetic effect in which not just the magnitude but the direction of the behavioral effect of a drug is determined by variation in sequence of its target gene. Equally, the fact that prior studies did not find such clear cut results attests to the many other factors that can obscure this relationship.</p><p>Finally, the findings have translational implications. COMT inhibitors are licensed as adjunctive therapy for Parkinson's disease and are under investigation in schizophrenia and other neuropsychiatric conditions (<xref rid="bib56 bib57" ref-type="bibr">56,57</xref>). Extending earlier findings (<xref rid="bib19 bib20" ref-type="bibr">19,20</xref>), our results show that <italic>COMT</italic> Val<sup>158</sup>Met genotype can affect the cognitive, behavioral, and perhaps affective responses to these drugs; genotype may also influence their toxicity (<xref rid="bib58" ref-type="bibr">58</xref>). Thus, genotype will be worth measuring in the ongoing trials and including in the design of future ones. However, the results will likely vary between COMT inhibitors according to their central bioavailability and pharmacokinetics, as well as between diseases depending on the nature and severity of dopaminergic involvement in their pathophysiology (<xref rid="bib4 bib59 bib60 bib61 bib62" ref-type="bibr">4,59&#x02013;62</xref>).</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>G.V.</given-names></name><name><surname>Goldman-Rakic</surname><given-names>P.S.</given-names></name></person-group><article-title>Modulation of memory fields by dopamine D1 receptors in prefrontal cortex</article-title><source>Nature</source><volume>376</volume><year>1995</year><fpage>572</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">7637804</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>A.</given-names></name><name><surname>Robbins</surname><given-names>T.</given-names></name></person-group><chapter-title>Neurochemical modulation of prefrontal cortical function in humans and animals</chapter-title><person-group person-group-type="editor"><name><surname>Stuss</surname><given-names>D.T.</given-names></name><name><surname>Knight</surname><given-names>R.T.</given-names></name></person-group><source>Principles of Frontal Lobes Function</source><year>2002</year><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford</publisher-loc><fpage>51</fpage><lpage>84</lpage></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>T.W.</given-names></name><name><surname>Arnsten</surname><given-names>A.F.T.</given-names></name></person-group><article-title>The neuropsychopharmacology of fronto-executive function: Monoaminergic modulation</article-title><source>Annu Rev Neurosci</source><volume>32</volume><year>2009</year><fpage>267</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">19555290</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>R.</given-names></name><name><surname>D'Esposito</surname><given-names>M.</given-names></name></person-group><article-title>Inverted-U-shaped dopamine actions on human working memory and cognitive control</article-title><source>Biol Psychiatry</source><volume>69</volume><year>2011</year><fpage>e113</fpage><lpage>e125</lpage><pub-id pub-id-type="pmid">21531388</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>D.R.</given-names></name><name><surname>Egan</surname><given-names>M.F.</given-names></name><name><surname>Bertolino</surname><given-names>A.</given-names></name><name><surname>Callicott</surname><given-names>J.H.</given-names></name><name><surname>Mattay</surname><given-names>V.S.</given-names></name><name><surname>Lipska</surname><given-names>B.A.</given-names></name></person-group><article-title>Prefrontal neurons and the genetics of schizophrenia</article-title><source>Biol Psychiatry</source><volume>50</volume><year>2001</year><fpage>825</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">11743939</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilder</surname><given-names>R.M.</given-names></name><name><surname>Volavka</surname><given-names>J.</given-names></name><name><surname>Lachman</surname><given-names>H.M.</given-names></name><name><surname>Grace</surname><given-names>A.A.</given-names></name></person-group><article-title>The catechol-<italic>O</italic>-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes</article-title><source>Neuropsychopharmacol</source><volume>29</volume><year>2004</year><fpage>1943</fpage><lpage>1961</lpage></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>E.M.</given-names></name><name><surname>Harrison</surname><given-names>P.J.</given-names></name><name><surname>Weinberger</surname><given-names>D.R.</given-names></name></person-group><article-title>Catechol-<italic>o</italic>-methyltransferase, cognition, and psychosis: Val<sup>158</sup>Met and beyond</article-title><source>Biol Psychiatry</source><volume>60</volume><year>2006</year><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">16476412</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durstewitz</surname><given-names>D.</given-names></name><name><surname>Seamans</surname><given-names>J.K.</given-names></name></person-group><article-title>The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-O-methyltransferase genotypes and schizophrenia</article-title><source>Biol Psychiatry</source><volume>64</volume><year>2008</year><fpage>739</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">18620336</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>D.</given-names></name><name><surname>Elvev&#x000e5;g</surname><given-names>B.</given-names></name></person-group><article-title>Genes, cognition and brain through a COMT lens</article-title><source>Neuroscience</source><volume>164</volume><year>2009</year><fpage>72</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">19446012</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.S.</given-names></name><name><surname>Lipska</surname><given-names>B.K.</given-names></name><name><surname>Halim</surname><given-names>N.</given-names></name><name><surname>Ma</surname><given-names>Q.D.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Melhem</surname><given-names>S.</given-names></name></person-group><article-title>Functional analysis of genetic variation in catechol-o-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain</article-title><source>Am J Hum Genet</source><volume>75</volume><year>2004</year><fpage>807</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">15457404</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slifstein</surname><given-names>M.</given-names></name><name><surname>Kolachana</surname><given-names>B.</given-names></name><name><surname>Simpson</surname><given-names>E.H.</given-names></name><name><surname>Tabares</surname><given-names>P.</given-names></name><name><surname>Cheng</surname><given-names>B.</given-names></name><name><surname>Duvall</surname><given-names>M.</given-names></name></person-group><article-title>COMT genotype predicts cortical-limbic D1 receptor availability measured with [C-11]NNC112 and PET</article-title><source>Mol Psychiatry</source><volume>13</volume><year>2008</year><fpage>821</fpage><lpage>827</lpage><pub-id pub-id-type="pmid">18317466</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>M.F.</given-names></name><name><surname>Goldberg</surname><given-names>T.E.</given-names></name><name><surname>Kolachana</surname><given-names>B.S.</given-names></name><name><surname>Callicott</surname><given-names>J.H.</given-names></name><name><surname>Mazzanti</surname><given-names>C.M.</given-names></name><name><surname>Straub</surname><given-names>R.E.</given-names></name></person-group><article-title>Effect of COMT Val<sup>108/158</sup> Met genotype on frontal lobe function and risk for schizophrenia</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><year>2001</year><fpage>6917</fpage><lpage>6922</lpage><pub-id pub-id-type="pmid">11381111</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mier</surname><given-names>D.</given-names></name><name><surname>Kirsch</surname><given-names>P.</given-names></name><name><surname>Meyer-Lindenberg</surname><given-names>A.</given-names></name></person-group><article-title>Neural substrates of pleiotropic action of genetic variation in COMT: A meta-analysis</article-title><source>Mol Psychiatry</source><volume>15</volume><year>2009</year><fpage>918</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">19417742</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Asper</surname><given-names>C.M.</given-names></name><name><surname>Goldberg</surname><given-names>T.E.</given-names></name><name><surname>Kolachana</surname><given-names>B.S.</given-names></name><name><surname>Straub</surname><given-names>R.E.</given-names></name><name><surname>Egan</surname><given-names>M.F.</given-names></name><name><surname>Weinberger</surname><given-names>D.R.</given-names></name></person-group><article-title>Genetic variation in catechol-O-methyltransferase: Effects on working memory in schizophrenic patients, their siblings, and healthy controls</article-title><source>Biol Psychiatry</source><volume>63</volume><year>2008</year><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">17707347</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>J.H.</given-names></name><name><surname>Scoriels</surname><given-names>L.</given-names></name><name><surname>Munafo</surname><given-names>M.R.</given-names></name></person-group><article-title>Meta-analysis of the cognitive effects of the catechol-<italic>O</italic>-methyltransferase gene val158/108met polymorphism</article-title><source>Biol Psychiatry</source><volume>64</volume><year>2008</year><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">18339359</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>E.M.</given-names></name><name><surname>Bannerman</surname><given-names>D.M.</given-names></name><name><surname>Sharp</surname><given-names>T.</given-names></name><name><surname>Harrison</surname><given-names>P.J.</given-names></name></person-group><article-title>Catechol-<italic>O</italic>-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex</article-title><source>J Neurosci</source><volume>24</volume><year>2004</year><fpage>5331</fpage><lpage>5335</lpage><pub-id pub-id-type="pmid">15190105</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapish</surname><given-names>C.C.</given-names></name><name><surname>Ahn</surname><given-names>S.</given-names></name><name><surname>Evangelista</surname><given-names>L.M.</given-names></name><name><surname>So</surname><given-names>K.</given-names></name><name><surname>Seamans</surname><given-names>J.K.</given-names></name><name><surname>Phillips</surname><given-names>A.G.</given-names></name></person-group><article-title>Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex</article-title><source>Psychopharmacol</source><volume>202</volume><year>2009</year><fpage>521</fpage><lpage>530</lpage></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasparini</surname><given-names>M.</given-names></name><name><surname>Fabrizio</surname><given-names>E.</given-names></name><name><surname>Bonifati</surname><given-names>V.</given-names></name><name><surname>Meco</surname><given-names>G.</given-names></name></person-group><article-title>Cognitive improvement during tolcapone treatment in Parkinson's disease</article-title><source>J Neural Transm</source><volume>104</volume><year>1997</year><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">9451720</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apud</surname><given-names>J.A.</given-names></name><name><surname>Mattay</surname><given-names>V.</given-names></name><name><surname>Chen</surname><given-names>J.S.</given-names></name><name><surname>Kolachana</surname><given-names>B.S.</given-names></name><name><surname>Callicott</surname><given-names>J.H.</given-names></name><name><surname>Rasetti</surname><given-names>R.</given-names></name></person-group><article-title>Tolcapone improves cognition and cortical information processing in normal human subjects</article-title><source>Neuropsychopharmacol</source><volume>32</volume><year>2007</year><fpage>1011</fpage><lpage>1020</lpage></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giakoumaki</surname><given-names>S.G.</given-names></name><name><surname>Roussos</surname><given-names>P.</given-names></name><name><surname>Bitsios</surname><given-names>P.</given-names></name></person-group><article-title>Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val(158)Met polymorphism</article-title><source>Neuropsychopharmacol</source><volume>33</volume><year>2008</year><fpage>3058</fpage><lpage>3068</lpage></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>P.</given-names></name><name><surname>Giakoumaki</surname><given-names>S.G.</given-names></name><name><surname>Bitsios</surname><given-names>P.</given-names></name></person-group><article-title>Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-<italic>O</italic>-methyltransferase rs4818C/G polymorphism</article-title><source>Biol Psychiatry</source><volume>66</volume><year>2009</year><fpage>997</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">19699472</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattay</surname><given-names>V.S.</given-names></name><name><surname>Goldberg</surname><given-names>T.E.</given-names></name><name><surname>Fera</surname><given-names>F.</given-names></name><name><surname>Hariri</surname><given-names>A.R.</given-names></name><name><surname>Tessitore</surname><given-names>A.</given-names></name><name><surname>Egan</surname><given-names>M.F.</given-names></name></person-group><article-title>Catechol <italic>O</italic>-methyltransferase val(158)-met genotype and individual variation in the brain response to amphetamine</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><year>2003</year><fpage>6186</fpage><lpage>6191</lpage><pub-id pub-id-type="pmid">12716966</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weickert</surname><given-names>T.W.</given-names></name><name><surname>Goldberg</surname><given-names>T.E.</given-names></name><name><surname>Mishara</surname><given-names>A.</given-names></name><name><surname>Apud</surname><given-names>J.A.</given-names></name><name><surname>Kolachana</surname><given-names>L.S.</given-names></name><name><surname>Egan</surname><given-names>M.F.</given-names></name></person-group><article-title>Catechol-<italic>O</italic>-methyltransferase <italic>Val</italic><sup><italic>108/158</italic></sup><italic>Met</italic> genotype predicts working memory response to antipsychotic medications</article-title><source>Biol Psychiatry</source><volume>56</volume><year>2004</year><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">15522252</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kereszturi</surname><given-names>E.</given-names></name><name><surname>Tarnok</surname><given-names>E.</given-names></name><name><surname>Bognar</surname><given-names>E.</given-names></name><name><surname>Lakatos</surname><given-names>K.</given-names></name><name><surname>Farkas</surname><given-names>L.</given-names></name><name><surname>Gadoros</surname><given-names>J.</given-names></name></person-group><article-title>Catechol-<italic>O</italic>-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><volume>147B</volume><year>2008</year><fpage>1431</fpage><lpage>1435</lpage><pub-id pub-id-type="pmid">18214865</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingemanse</surname><given-names>J.</given-names></name><name><surname>Jorga</surname><given-names>K.M.</given-names></name><name><surname>Schmitt</surname><given-names>M.</given-names></name><name><surname>Gieschke</surname><given-names>R.</given-names></name><name><surname>Fotteler</surname><given-names>B.</given-names></name><name><surname>Zurcher</surname><given-names>G.</given-names></name></person-group><article-title>Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans</article-title><source>Clin Pharmacol Ther</source><volume>57</volume><year>1995</year><fpage>508</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">7768073</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceravolo</surname><given-names>R.</given-names></name><name><surname>Piccini</surname><given-names>P.</given-names></name><name><surname>Bailey</surname><given-names>D.L.</given-names></name><name><surname>Jorga</surname><given-names>K.M.</given-names></name><name><surname>Bryson</surname><given-names>H.</given-names></name><name><surname>Brooks</surname><given-names>D.J.</given-names></name></person-group><article-title><sup>18</sup>F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease</article-title><source>Synapse</source><volume>43</volume><year>2002</year><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">11793426</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorga</surname><given-names>K.M.</given-names></name></person-group><article-title>Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: A review of early studies in volunteers</article-title><source>Neurology</source><volume>50</volume><issue>suppl</issue><year>1998</year><fpage>S31</fpage><lpage>S38</lpage><pub-id pub-id-type="pmid">9591520</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>E.M.</given-names></name><name><surname>Burnet</surname><given-names>P.W.J.</given-names></name><name><surname>Sodhi</surname><given-names>M.S.</given-names></name><name><surname>Harrison</surname><given-names>P.J.</given-names></name></person-group><article-title>Catechol-<italic>o</italic>-methyltransferase and proline dehydrogenase messenger RNA in the prefrontal cortex in schizophrenia, bipolar disorder and major depression</article-title><source>Synapse</source><volume>51</volume><year>2004</year><fpage>112</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">14618678</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callicott</surname><given-names>J.H.</given-names></name><name><surname>Ramsey</surname><given-names>N.F.</given-names></name><name><surname>Tallent</surname><given-names>K.</given-names></name><name><surname>Bertolino</surname><given-names>A.</given-names></name><name><surname>Knable</surname><given-names>M.B.</given-names></name><name><surname>Coppola</surname><given-names>R.</given-names></name></person-group><article-title>Functional magnetic resonance imaging brain mapping in psychiatry: Methodological issues illustrated in a study of working memory in schizophrenia</article-title><source>Neuropsychopharmacol</source><volume>18</volume><year>1998</year><fpage>186</fpage><lpage>196</lpage></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehring</surname><given-names>W.J.</given-names></name><name><surname>Willoughby</surname><given-names>A.R.</given-names></name></person-group><article-title>The medial frontal cortex and the rapid processing of monetary gains and losses</article-title><source>Science</source><volume>295</volume><year>2002</year><fpage>2279</fpage><lpage>2282</lpage><pub-id pub-id-type="pmid">11910116</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marco-Pallar&#x000e9;s</surname><given-names>J.</given-names></name><name><surname>Cucurell</surname><given-names>D.</given-names></name><name><surname>Cunillera</surname><given-names>T.</given-names></name><name><surname>Kr&#x000e4;mer</surname><given-names>U.M.</given-names></name><name><surname>C&#x000e0;mara</surname><given-names>E.</given-names></name><name><surname>Nager</surname><given-names>W.</given-names></name></person-group><article-title>Genetic variability in the dopamine system (dopamine receptor D4, COMT) modulates neurophysiological responses to gains and losses</article-title><source>Biol Psychiatry</source><volume>66</volume><year>2009</year><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">19251248</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmack</surname><given-names>K.</given-names></name><name><surname>Schlagenhauf</surname><given-names>F.</given-names></name><name><surname>Sterzer</surname><given-names>P.</given-names></name><name><surname>Puls</surname><given-names>I.</given-names></name><name><surname>Sander</surname><given-names>T.</given-names></name><name><surname>Heinz</surname><given-names>A.</given-names></name></person-group><article-title>Catechol-<italic>O</italic>-methyltransferase val(158)met genotype influences neural processing of reward anticipation</article-title><source>Neuroimage</source><volume>42</volume><year>2008</year><fpage>1631</fpage><lpage>1638</lpage><pub-id pub-id-type="pmid">18634888</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camara</surname><given-names>E.</given-names></name><name><surname>Kramer</surname><given-names>U.M.</given-names></name><name><surname>Cunillera</surname><given-names>T.</given-names></name><name><surname>Marco-Pallares</surname><given-names>J.</given-names></name><name><surname>Cucurell</surname><given-names>D.</given-names></name><name><surname>Nager</surname><given-names>W.</given-names></name></person-group><article-title>The effects of COMT (Val108/158Met) and DRD4 (SNP-521) dopamine genotypes on brain activations related to valence and magnitude of rewards</article-title><source>Cereb Cortex</source><volume>20</volume><year>2010</year><fpage>1985</fpage><lpage>1996</lpage><pub-id pub-id-type="pmid">20038544</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer-Lindenberg</surname><given-names>A.</given-names></name><name><surname>Nichols</surname><given-names>T.</given-names></name><name><surname>Callicott</surname><given-names>J.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Kolachana</surname><given-names>B.</given-names></name><name><surname>Buckholtz</surname><given-names>J.</given-names></name></person-group><article-title>Impact of complex genetic variation on COMT on human brain function</article-title><source>Mol Psychiatry</source><volume>11</volume><year>2006</year><fpage>867</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">16786032</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nackley</surname><given-names>A.G.</given-names></name><name><surname>Shabalania</surname><given-names>S.A.</given-names></name><name><surname>Tchivileva</surname><given-names>I.E.</given-names></name><name><surname>Satterfield</surname><given-names>K.</given-names></name><name><surname>Korchynski</surname><given-names>O.</given-names></name><name><surname>Makarov</surname><given-names>S.S.</given-names></name></person-group><article-title>Human catechol-<italic>O</italic>-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure</article-title><source>Science</source><volume>314</volume><year>2006</year><fpage>1930</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">17185601</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ursini</surname><given-names>G.</given-names></name><name><surname>Bollati</surname><given-names>V.</given-names></name><name><surname>Fazio</surname><given-names>L.</given-names></name><name><surname>Porcelli</surname><given-names>A.</given-names></name><name><surname>Iacovelli</surname><given-names>L.</given-names></name><name><surname>Catalani</surname><given-names>A.</given-names></name></person-group><article-title>Stress-related methylation of the catechol-<italic>O</italic>-methyltransferase val(158) allele predicts human prefrontal cognition and activity</article-title><source>J Neurosci</source><volume>31</volume><year>2011</year><fpage>6692</fpage><lpage>6698</lpage><pub-id pub-id-type="pmid">21543598</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertolino</surname><given-names>A.</given-names></name><name><surname>Blasi</surname><given-names>G.</given-names></name><name><surname>Latorre</surname><given-names>V.</given-names></name><name><surname>Rubino</surname><given-names>V.</given-names></name><name><surname>Rampino</surname><given-names>A.</given-names></name><name><surname>Sinibaldi</surname><given-names>L.</given-names></name></person-group><article-title>Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in humans</article-title><source>J Neurosci</source><volume>26</volume><year>2006</year><fpage>3918</fpage><lpage>3922</lpage><pub-id pub-id-type="pmid">16611807</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>M.J.</given-names></name><name><surname>Moustafa</surname><given-names>A.A.</given-names></name><name><surname>Haughley</surname><given-names>H.M.</given-names></name><name><surname>Curran</surname><given-names>T.</given-names></name><name><surname>Hutchison</surname><given-names>K.E.</given-names></name></person-group><article-title>Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><year>2007</year><fpage>16311</fpage><lpage>16316</lpage><pub-id pub-id-type="pmid">17913879</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prata</surname><given-names>D.P.</given-names></name><name><surname>Mechelli</surname><given-names>A.</given-names></name><name><surname>Fu</surname><given-names>C.H.</given-names></name><name><surname>Picchioni</surname><given-names>M.</given-names></name><name><surname>Toulopoulou</surname><given-names>T.</given-names></name><name><surname>Bramon</surname><given-names>E.</given-names></name></person-group><article-title>Epistasis between the DAT 3&#x02032; UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia</article-title><source>Proc Natl Acad Sci U S A</source><volume>106</volume><year>2009</year><fpage>13600</fpage><lpage>13605</lpage><pub-id pub-id-type="pmid">19666577</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>T.E.</given-names></name><name><surname>Egan</surname><given-names>M.F.</given-names></name><name><surname>Gscheidle</surname><given-names>T.</given-names></name><name><surname>Coppola</surname><given-names>R.</given-names></name><name><surname>Weickert</surname><given-names>T.</given-names></name><name><surname>Kolachana</surname><given-names>B.S.</given-names></name></person-group><article-title>Executive subprocesses in working memory: Relationship to catechol-<italic>O</italic>-methyltransferase Val158Met genotype and schizophrenia</article-title><source>Arch Gen Psychiatry</source><volume>60</volume><year>2003</year><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="pmid">12963670</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>M.M.</given-names></name><name><surname>Chamberlain</surname><given-names>S.R.</given-names></name><name><surname>Roiser</surname><given-names>J.</given-names></name><name><surname>Robbins</surname><given-names>T.W.</given-names></name><name><surname>Muller</surname><given-names>U.</given-names></name></person-group><article-title>Effects of two dopamine-modulating genes (<italic>DAT1</italic> 9/10 and COMT Val/Met) on n-back working memory performance in healthy volunteers</article-title><source>Psychol Med</source><volume>41</volume><year>2011</year><fpage>611</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">21272388</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>D.</given-names></name><name><surname>Weinberger</surname><given-names>D.R.</given-names></name><name><surname>Malhotra</surname><given-names>A.K.</given-names></name><name><surname>Goldberg</surname><given-names>T.E.</given-names></name></person-group><article-title>The role of COMT Val158Met in cognition</article-title><source>Biol Psychiatry</source><volume>65</volume><year>2009</year><fpage>e1</fpage><lpage>e2</lpage><pub-id pub-id-type="pmid">18838132</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>P.J.</given-names></name><name><surname>Tunbridge</surname><given-names>E.M.</given-names></name></person-group><article-title>Catechol-<italic>O</italic>-methyltransferase (COMT): A gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders</article-title><source>Neuropsychopharmacol</source><volume>33</volume><year>2008</year><fpage>3037</fpage><lpage>3045</lpage></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>E.</given-names></name><name><surname>D'Esposito</surname><given-names>M.</given-names></name></person-group><article-title>Estrogen shapes dopamine-dependent cognitive processes: Implications for women's health</article-title><source>J Neurosci</source><volume>31</volume><year>2011</year><fpage>5286</fpage><lpage>5293</lpage><pub-id pub-id-type="pmid">21471363</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tunbridge</surname><given-names>E.M.</given-names></name><name><surname>Weickert</surname><given-names>C.S.</given-names></name><name><surname>Kleinman</surname><given-names>J.E.</given-names></name><name><surname>Herman</surname><given-names>M.M.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Kolachana</surname><given-names>B.S.</given-names></name></person-group><article-title>Catechol-<italic>o</italic>-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan</article-title><source>Cereb Cortex</source><volume>17</volume><year>2007</year><fpage>1206</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">16835293</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumontheil</surname><given-names>I.</given-names></name><name><surname>Roggeman</surname><given-names>C.</given-names></name><name><surname>Ziermans</surname><given-names>T.</given-names></name><name><surname>Peyrard-Janvid</surname><given-names>M.</given-names></name><name><surname>Matsson</surname><given-names>H.</given-names></name><name><surname>Kere</surname><given-names>J.</given-names></name></person-group><article-title>Influence of the COMT genotype on working memory and brain activity changes during development</article-title><source>Biol Psychiatry</source><volume>70</volume><year>2011</year><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">21514925</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yacubian</surname><given-names>J.</given-names></name><name><surname>Sommer</surname><given-names>T.</given-names></name><name><surname>Schroeder</surname><given-names>K.</given-names></name><name><surname>Glascher</surname><given-names>J.</given-names></name><name><surname>Kalisch</surname><given-names>R.</given-names></name><name><surname>Leuenberger</surname><given-names>B.</given-names></name></person-group><article-title>Gene-gene interaction associated with neural reward sensitivity</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><year>2007</year><fpage>8125</fpage><lpage>8130</lpage><pub-id pub-id-type="pmid">17483451</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krugel</surname><given-names>L.K.</given-names></name><name><surname>Biele</surname><given-names>G.</given-names></name><name><surname>Mohr</surname><given-names>P.N.C.</given-names></name><name><surname>Li</surname><given-names>S.C.</given-names></name><name><surname>Heekeren</surname><given-names>H.R.</given-names></name></person-group><article-title>Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions</article-title><source>Proc Natl Acad Sci U S A</source><volume>106</volume><year>2009</year><fpage>17951</fpage><lpage>17956</lpage><pub-id pub-id-type="pmid">19822738</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>M.J.</given-names></name><name><surname>Fossella</surname><given-names>J.A.</given-names></name></person-group><article-title>Neurogenetics and pharmacology of learning, motivation, and cognition</article-title><source>Neuropsychopharmacol</source><volume>36</volume><year>2011</year><fpage>133</fpage><lpage>152</lpage></element-citation></ref><ref id="bib50"><label>50</label><mixed-citation publication-type="other">Tunbridge EM, Huber A, Farrell SM, Stumpenhorst K, Harrison PJ, Walton M (in press): The role of catechol-O-methyltransferase (COMT) in reward processing and addiction. <italic>CNS Neurol Disord Drug Targets</italic>.</mixed-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>N.W.</given-names></name><name><surname>Montgomery</surname><given-names>K.S.</given-names></name><name><surname>Beas</surname><given-names>B.S.</given-names></name><name><surname>Mitchell</surname><given-names>M.R.</given-names></name><name><surname>LaSarge</surname><given-names>C.I.</given-names></name><name><surname>Mendez</surname><given-names>I.A.</given-names></name></person-group><article-title>Dopaminergic modulation of risky decision-making</article-title><source>J Neurosci</source><volume>31</volume><year>2011</year><fpage>17460</fpage><lpage>17470</lpage><pub-id pub-id-type="pmid">22131407</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasi</surname><given-names>G.</given-names></name><name><surname>Mattay</surname><given-names>V.S.</given-names></name><name><surname>Bertolino</surname><given-names>A.</given-names></name><name><surname>Elvev&#x000e5;g</surname><given-names>B.</given-names></name><name><surname>Callicott</surname><given-names>J.H.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name></person-group><article-title>Effect of catechol-<italic>O</italic>-methyltransferase <italic>val158met</italic> genotype on attentional control</article-title><source>J Neurosci</source><volume>25</volume><year>2005</year><fpage>5038</fpage><lpage>5045</lpage><pub-id pub-id-type="pmid">15901785</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>P.</given-names></name><name><surname>Giakoumaki</surname><given-names>S.G.</given-names></name><name><surname>Rogdaki</surname><given-names>M.</given-names></name><name><surname>Pavlakis</surname><given-names>S.</given-names></name><name><surname>Frangou</surname><given-names>S.</given-names></name><name><surname>Bitios</surname><given-names>P.</given-names></name></person-group><article-title>Prepulse inhibition of the startle reflex depends on the catechol <italic>O</italic>-methyltransferase Val158Met gene polymorphism</article-title><source>Psychol Med</source><volume>38</volume><year>2008</year><fpage>1651</fpage><lpage>1658</lpage><pub-id pub-id-type="pmid">18261249</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolka</surname><given-names>M.N.</given-names></name><name><surname>Schumann</surname><given-names>G.</given-names></name><name><surname>Wrase</surname><given-names>J.</given-names></name><name><surname>Grusser</surname><given-names>S.M.</given-names></name><name><surname>Flor</surname><given-names>H.</given-names></name><name><surname>Mann</surname><given-names>K.</given-names></name></person-group><article-title>Catechol-<italic>O</italic>-methyltransferase <italic>val</italic><sup><italic>158</italic></sup><italic>met</italic> genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex</article-title><source>J Neurosci</source><volume>25</volume><year>2005</year><fpage>836</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">15673663</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaleo</surname><given-names>F.</given-names></name><name><surname>Crawley</surname><given-names>J.N.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Lipska</surname><given-names>B.K.</given-names></name><name><surname>Pickel</surname><given-names>J.</given-names></name><name><surname>Weinberger</surname><given-names>D.R.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Genetic dissection of the role of catechol-<italic>O</italic>-methyltransferase in cognition and stress reactivity in mice</article-title><source>J Neurosci</source><volume>28</volume><year>2008</year><fpage>8709</fpage><lpage>8723</lpage><pub-id pub-id-type="pmid">18753372</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apud</surname><given-names>J.A.</given-names></name><name><surname>Weinberger</surname><given-names>D.R.</given-names></name></person-group><article-title>Treatment of cognitive deficits associated with schizophrenia: Potential role of catechol-<italic>O</italic>-methyltransferase inhibitors</article-title><source>CNS Drugs</source><volume>21</volume><year>2007</year><fpage>535</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">17579498</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitsios</surname><given-names>P.</given-names></name><name><surname>Roussos</surname><given-names>P.</given-names></name></person-group><article-title>Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia</article-title><source>Pharmacogenomics</source><volume>12</volume><year>2011</year><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">21521027</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>P.</given-names></name><name><surname>Tian</surname><given-names>Q.</given-names></name><name><surname>Ji</surname><given-names>Y.</given-names></name><name><surname>Ren-Patterson</surname><given-names>R.</given-names></name></person-group><article-title>Orientation and cellular distribution of membrane-bound catechol-<italic>O</italic>-methyltransferase in cortical neurons: Implications for drug development</article-title><source>J Biol Chem</source><volume>286</volume><year>2011</year><fpage>34752</fpage><lpage>34760</lpage><pub-id pub-id-type="pmid">21846718</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>R.</given-names></name><name><surname>Barker</surname><given-names>R.A.</given-names></name><name><surname>Sahakian</surname><given-names>B.J.</given-names></name><name><surname>Robbins</surname><given-names>T.R.</given-names></name></person-group><article-title>Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands</article-title><source>Cereb Cortex</source><volume>11</volume><year>2001</year><fpage>1136</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">11709484</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foltynie</surname><given-names>T.</given-names></name><name><surname>Goldberg</surname><given-names>T.</given-names></name><name><surname>Lewis</surname><given-names>S.</given-names></name><name><surname>Blackwell</surname><given-names>A.</given-names></name><name><surname>Weinberger</surname><given-names>D.</given-names></name><name><surname>Robbins</surname><given-names>T.</given-names></name></person-group><article-title>Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism</article-title><source>Mov Disord</source><volume>19</volume><year>2004</year><fpage>885</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">15300652</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prata</surname><given-names>D.P.</given-names></name><name><surname>Mechelli</surname><given-names>A.</given-names></name><name><surname>Fu</surname><given-names>C.</given-names></name><name><surname>Picchioni</surname><given-names>M.</given-names></name><name><surname>Kane</surname><given-names>F.</given-names></name><name><surname>Kalidindi</surname><given-names>S.</given-names></name></person-group><article-title>Opposite effects of COMT Val158Met on cortical function in healthy subjects and patients with schizophrenia</article-title><source>Biol Psychiatry</source><volume>65</volume><year>2009</year><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">19054502</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>M.</given-names></name><name><surname>Mehta</surname><given-names>M.A.</given-names></name></person-group><article-title>Cognitive enhancement by drugs in health and disease</article-title><source>Trends Cogn Sci</source><volume>15</volume><year>2011</year><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">21146447</pub-id></element-citation></ref></ref-list><sec id="sec6" sec-type="supplementary-material"><title>Supplementary data</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplement 1</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material></p></sec><ack><p>The work was funded by a Wellcome Trust doctoral studentship (SMF). EMT holds a Royal Society University Research Fellowship. Additional support provided by a <funding-source>Wellcome Trust</funding-source> grant to the Oxford Centre for Human Brain Activity. We thank Guy Goodwin, Catherine Harmer, and Robert Rogers for helpful comments on the manuscript and Daniel Weinberger for many insightful discussions. We also thank him and Richard Coppola for the N-back script.</p><p>PJH reports having received lecture fees from AstraZeneca, Janssen, Otsuka and Takeda, and consulting fees from Merck. SMF, EMT, and SB report no biomedical financial interests or potential conflicts of interest.</p></ack><fn-group><fn id="sec5" fn-type="supplementary-material"><p>Supplementary material cited in this article is available online.</p></fn></fn-group></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Interactive behavioral effects of catechol-<italic>O</italic>-methyltransferase (<italic>COMT</italic>) genotype and COMT inhibition. <bold>(A)</bold> 0-back: main effect of drug [<italic>F</italic>(1,56) = 4.14, <italic>p =</italic> .047] and genotype &#x000d7; drug interaction [<italic>F</italic>(1,56) = 6.75, <italic>p =</italic> .012]. Met-COMT subjects given tolcapone perform worse than those given placebo. <bold>(B)</bold> 1-back: genotype &#x000d7; drug interaction [<italic>F</italic>(1,56) = 9.26, <italic>p =</italic> .006]. Tolcapone impairs performance in Met-COMT subjects and, as a trend, improves it in Val-COMT subjects, compared with their respective placebo groups. <bold>(C)</bold> 2-back: genotype &#x000d7; drug interaction [<italic>F</italic>(1,56) = 13.62, <italic>p =</italic> .001]. Met-COMT subjects perform better than Val-COMT subjects on placebo. Tolcapone reverses this difference, impairing Met-COMT subjects and enhancing Val-COMT subjects, compared with their respective placebo groups. <bold>(D)</bold> 3-back. Genotype &#x000d7; drug interaction [<italic>F</italic>(1,56) = 8.03, <italic>p =</italic> .006]. Val-COMT subjects given tolcapone perform better than those given placebo. <bold>(E)</bold> Gambling task, showing percentage of times when 5 not 25 was gambled. Genotype &#x000d7; drug interaction [<italic>F</italic>(1,61) = 7.91, <italic>p =</italic> .007]. On placebo, Met-COMT subjects are more likely than Val-COMT subjects to make a small rather than a large bet. Tolcapone reverses this difference, making Val-COMT subjects significantly more risk averse, compared with those given placebo. <bold>(F)</bold> Happiness visual analogue scale (VAS) ratings for tolcapone-treated subjects. Data are adjusted means with standard errors. Time 1: immediately before drug administration. Time 2: T1 + 90 min. 3: T1 + 210 minutes. *<italic>p =</italic> .026. See <xref rid="sec6" ref-type="sec">Table S2 in Supplement 1</xref> for happiness VAS ratings in the placebo groups.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Catechol-<italic>O</italic>-methyltransferase (<italic>COMT</italic>) genotype, inhibition, and the dopaminergic inverted-U. Val-COMT subjects have higher COMT activity and thus lower dopamine tone than Met-COMT subjects, and therefore sit further to the left on the curve. After tolcapone, all subjects move to the right because dopamine signaling increases. However, the functional correlates of this shift differ between genotypes. On the N-back task, Val-COMT subjects move closer to the optimum, whereas Met-COMT subjects are now to the right of the peak. A similar principle applies to the gambling task, although in this case, the y axis is not performance but risk aversion.</p></caption><graphic xlink:href="gr2"/><attrib>Idea from Tunbridge <italic>et al.</italic> (<xref rid="bib7" ref-type="bibr">7</xref>) and Mattay <italic>et al.</italic> (<xref rid="bib22" ref-type="bibr">22</xref>).</attrib></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Demographics of Subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="center">Met-COMT, Placebo</th><th align="center">Val-COMT, Placebo</th><th align="center">Met-COMT, Placebo</th><th align="center">Met-COMT, Placebo</th><th align="center">ANOVA, <italic>p</italic></th></tr></thead><tbody><tr><td align="left">Number<xref rid="tblfn1" ref-type="table-fn">a</xref></td><td align="center">18</td><td align="center">16</td><td align="center">16</td><td align="center">17</td><td/></tr><tr><td align="left">Ethnicity<xref rid="tblfn2" ref-type="table-fn">b</xref></td><td align="center">17C, 1I</td><td align="center">12C, 2I, 1Ch, 1A</td><td align="center">16C</td><td align="center">14C, 2I, 1Ch</td><td/></tr><tr><td align="left">Age (Years)</td><td align="char">22.6&#x000a0;(3.2)</td><td align="center">24.0&#x000a0;(5.1)</td><td align="center">24.4&#x000a0;(9.0)</td><td align="center">23.9&#x000a0;(3.9)</td><td align="char">.80</td></tr><tr><td align="left">NART</td><td align="char">118&#x000a0;(4)</td><td align="center">117&#x000a0;(5)</td><td align="center">115&#x000a0;(5)</td><td align="center">116&#x000a0;(6)</td><td align="char">.23</td></tr><tr><td align="left">Alcohol (Units/Week)</td><td align="char">10&#x000a0;(7)</td><td align="center">8&#x000a0;(5)</td><td align="center">7&#x000a0;(5)</td><td align="center">8&#x000a0;(8)</td><td align="char">.59</td></tr><tr><td align="left">Cigarettes/Day</td><td align="char">0&#x000a0;(0)</td><td align="center">.4&#x000a0;(1.3)</td><td align="center">.4&#x000a0;(1.5)</td><td align="center">.2&#x000a0;(.7)</td><td align="char">.60</td></tr><tr><td align="left">BDI</td><td align="char">3.9&#x000a0;(5.3)</td><td align="center">3.5&#x000a0;(3.3)</td><td align="center">3.7&#x000a0;(3.7)</td><td align="center">3.1&#x000a0;(2.9)</td><td align="char">.89</td></tr><tr><td align="left">STAI</td><td align="char">32&#x000a0;(8)</td><td align="center">39&#x000a0;(7)</td><td align="center">33&#x000a0;(10)</td><td align="center">37&#x000a0;(8)</td><td align="char">.09</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (SD).</p><p>ANOVA, analysis of variance; BDI, Beck Depression Inventory; COMT, catechol-<italic>O</italic>-methyltransferase Val<sup>158</sup>Met genotype; NART, National Adult Reading Test; STAI, Spielberger Trait Anxiety Inventory.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn1"><label>a</label><p>Seven subjects completed the gambling task but not the N-back. Final sample size for the N-back task was as follows: <italic>n</italic> = 15 (Met-COMT placebo), 15 (Val-COMT placebo), 16 (Met-COMT tolcapone), and 14 (Val-COMT tolcapone). The demographics of the 60 who completed the N-back were virtually identical to those given here for the whole sample.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>b</label><p>C, Caucasian; Ch, Chinese; I, Indian; A, African Caribbean.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Reaction Times and Additional Gambling Task Data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="center">Met-COMT, Placebo</th><th align="center">Val-COMT, Placebo</th><th align="center">Met-COMT, Tolcapone</th><th align="center">Val-COMT, Tolcapone</th></tr></thead><tbody><tr><td align="left">N-Back Task<xref rid="tblfn3" ref-type="table-fn">a</xref> (msec)</td><td/><td/><td/><td/></tr><tr><td align="left">&#x000a0;0-Back RT</td><td align="char">504&#x000a0;(99)</td><td align="char">494&#x000a0;(68)</td><td align="char">531&#x000a0;(104)</td><td align="char">488&#x000a0;(65)</td></tr><tr><td align="left">&#x000a0;1-Back RT</td><td align="char">540&#x000a0;(199)</td><td align="char">627&#x000a0;(200)</td><td align="char">608&#x000a0;(200)</td><td align="char">497&#x000a0;(172)</td></tr><tr><td align="left">&#x000a0;2-Back RT</td><td align="char">653&#x000a0;(237)</td><td align="char">844&#x000a0;(256)</td><td align="char">693&#x000a0;(233)</td><td align="char">687&#x000a0;(282)</td></tr><tr><td align="left">&#x000a0;3-Back RT</td><td align="char">706&#x000a0;(290)</td><td align="char">916&#x000a0;(269)</td><td align="char">690&#x000a0;(255)</td><td align="char">707&#x000a0;(245)</td></tr><tr><td align="left">Gambling Task<xref rid="tblfn4" ref-type="table-fn">b</xref></td><td/><td/><td/><td/></tr><tr><td align="left">&#x000a0;RT (msec)</td><td align="char">730&#x000a0;(333)</td><td align="char">715&#x000a0;(331)</td><td align="char">884&#x000a0;(557)</td><td align="char">667&#x000a0;(187)</td></tr><tr><td align="left">&#x000a0;Choose 5 after 2 gains<xref rid="tblfn5" ref-type="table-fn">c</xref> (%)</td><td align="char">57&#x000a0;(21)</td><td align="char">50&#x000a0;(17)</td><td align="char">47&#x000a0;(19)</td><td align="char">63&#x000a0;(18)</td></tr><tr><td align="left">&#x000a0;Choose 5 after 2 losses<xref rid="tblfn6" ref-type="table-fn">d</xref> (%)</td><td align="char">45&#x000a0;(22)</td><td align="char">34&#x000a0;(15)</td><td align="char">38&#x000a0;(16)</td><td align="char">50&#x000a0;(18)</td></tr></tbody></table><table-wrap-foot><fn><p>Values are mean (SD).</p><p>COMT, catechol-<italic>O</italic>-methyltransferase Val<sup>158</sup>Met genotype; RT, reaction time.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn3"><label>a</label><p>RT not available for three subjects. For statistics, see text.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn4"><label>b</label><p>RT not available for 10 subjects.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn5"><label>c</label><p>Genotype &#x000d7; drug interaction [<italic>F</italic>(1,61) = 5.96, <italic>p =</italic> .018]. For subjects on tolcapone, Val-COMT &#x0003e; Met-COMT, <italic>p =</italic> .036.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn6"><label>d</label><p>Genotype &#x000d7; drug interaction [<italic>F</italic>(1,61) = 6.65, <italic>p =</italic> .012]. For subjects on tolcapone, Val-COMT &#x0003e; Met-COMT, <italic>p =</italic> .023. For Val-COMT, tolcapone &#x0003e; placebo, <italic>p =</italic> .043.</p></fn></table-wrap-foot></table-wrap></floats-group></article>